Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.
Ceftazidime is a new antimicrobial agent possessing excellent in vitro activity against most members of the family Enterobacteriaceae and against Pseudomonas aeruginosa. We conducted a double-blind, prospective, multicenter trial to compare ceftazidime with moxalactam in the treatment of serious gra...
محفوظ في:
| الحاوية / القاعدة: | Antimicrob Agents Chemother |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
American Society for Microbiology (ASM)
1986
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC176442/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3530128/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.30.1.90 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|